drugset / Trial / NCT07334860

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

NCT07334860

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelBasic science

Summary

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine. The goals of the trial are to learn: * What happens to different forms of MK-1167 in a healthy person's body over time * About the safety of MK-1167 and if people tolerate it

Timeline

Start
2026-02-06
Primary completion
2026-05-20
Completion
2026-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-1167 Unknown Oral

Indications

No indication recorded.